Page 8 - Sanket Koul

UK sees rise in Indian students, boosts research ties: UCL President

University College London sees a 19-26% surge in Indian student enrolments for academic year 2025-26, focusing on partnerships and scholarships instead of a foreign campus

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug

According to the agreement, Immutep will receive from Dr Reddy's an upfront payment of $20 million (around AUD 30.2 million)

Health care sector welcomes Bill that taxes pan masala production

Industry says earmarking funds for public health at par with national security will help channel revenue for public health infra

Patient bodies seek Russia-like funding for rare diseases treatment

A leading rare disease group urges India to adopt a Russia-style dedicated fund and tax-based model to ensure sustained treatment support beyond the current ₹50-lakh cap

Smartworld enters Noida with 6-acre land buy; ₹2,000 cr project planned

The company said that the project will have a total development cost of ₹2,000 crore, with the gross sale value projected at over ₹3,000 crore

BorderPlus to send 1,000 Indian nurses to Gulf Cooperation Council by FY27

GCC healthcare ecosystem projected to require over 50,000 additional nurses by 2027, says BorderPlus CEO

IITs' push to broaden job profiles pays dividends with diverse offers

Hedge funds and trading firms outpace start-ups in placement drives

Birla Estates partners Sikka Group to co-develop ₹1,600 cr Noida project

Birla Estates has tied up with Sikka Group to co-develop a ₹1,600-crore Greater Noida housing project, leveraging new revival policies that allow creditworthy developers to take over stalled projects

DRL semaglutide ruling may set precedent for generic makers: Experts

Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases

WHO issues first guidelines backing GLP-1 drugs for obesity management

WHO has issued its first guidelines recommending GLP-1 drugs for long-term obesity treatment in adults, while stressing equitable access, health system readiness and lifestyle support

Metropolis launches GLP-1 monitoring test packages, targets obesity market

Metropolis Healthcare has rolled out three TruHealth GLP-1 test packages for patients preparing for or undergoing obesity treatment, as diagnostics firms move to tap the fast-growing segment

IITs see strong recruiter rush on Day 1 as top firms roll out big offers

Day 1 of IIT placements saw a surge of top recruiters, with NVIDIA, Amazon, Zomato, Google and Flipkart among those offering high-value roles, as more students opted for final placements over PPOs

PMJAY for 70+ logged 700k treatments worth ₹1,471 crore in first year

Centre to ramp up awareness, with 15% of the 60 million senior citizen target covered, even as experts flag budgetary issues, slow pace

CDSCO committee considers avoiding high-risk solvents in kids' oral drugs

Move follows reports of deaths from contaminated cough syrups in Chhindwara

Mount K Kapital raises 2nd realty fund worth ₹4K cr, to expand beyond MMR

The seven-year credit fund will back 10-15 projects across major cities, building on the firm's first Rs 790 crore vehicle

HDFC Capital, Hero Realty set up ₹1K cr platform for mid-income housing

HDFC Capital has tied up with Hero Realty to build a Rs 1,000 crore mid-income housing platform aimed at accelerating development across Tier 1 and Tier 2 cities

CDSCO panel seeks uniform enforcement of drug standards across states

The DCC has asked the Centre to address gaps in drug-standard enforcement, write to states on non-uniform norms and improve testing and regulatory infrastructure highlighted under the SHRESTH index

Affordable homes lose investor appeal as luxury delivers higher returns

With luxury home prices rising faster than affordable units and branded developers driving demand in prime locations, investors are shifting towards premium and luxury housing

Eris Lifesciences to acquire 30% stake in Swiss Parenterals for ₹423 cr

Eris Lifesciences will purchase the final 30% stake in Swiss Parenterals through a Rs 423-crore share swap, aiming for full consolidation, greater cost efficiency and strengthened strategic control